Biocon Ltd Share Price – NSE  / BSE

Pharmaceuticals, Small Cap

Biocon will hold a meeting of the Board of Directors of the Company on 6 December 2025.

Powered by Capital Market - Live News

The fund raising could also be done through issue of equity shares or any other eligible securities, through one or more permissible modes including but not limited to qualified institutions placement, rights issue, preferential issue and further public offer etc., in one or more tranches.

The company?s board will also consider a proposal for investment in Biocon Biologics (BBL), an unlisted material subsidiary of the company, by way of purchase or acquisition of securities from shareholders of BBL, for cash and/or consideration other than cash through issuance and allotment of fully paid-up equity shares of the company on a preferential allotment basis through private placement.

Biocon is a global biopharma company dedicated to improving affordable access to therapies for chronic conditions such as diabetes, cancer, and autoimmune diseases.

On a consolidated basis, Biocon reported net profit of Rs 84.50 crore in Q2 September 2025 as against net loss of Rs 16 crore in Q2 September 2024. Net sales rose 20.24% YoY to Rs 4262.50 crore in Q2 September 2025.

The scrip fell 4.68% to currently trade at Rs 390.95 on the BSE.

Powered by Capital Market - Live News

The brokerage reduced Biocon?s target to Rs 360 from Rs 430, implying a downside of 12.20% from the previous close of Rs 410. It said the company?s valuation has become expensive.

The broker trimmed valuation multiples across key business segments. The biosimilars business multiple was cut to 14x EBITDA from 20x, citing deteriorating market conditions and evolving USFDA guidelines. The generics division multiple was reduced to 14x from 16x due to weaker margins.

The brokerage acknowledged Biocon's strong global position in biosimilar R&D and execution, but warned that pricing pressure and an increasingly crowded competitive pipeline may hold back sales and keep earnings below earlier expectations.

Biocon is a global biopharma company dedicated to improving affordable access to therapies for chronic conditions such as diabetes, cancer, and autoimmune diseases.

On a consolidated basis, Biocon reported net profit of Rs 84.50 crore in Q2 September 2025 as against net loss of Rs 16 crore in Q2 September 2024. Net sales rose 20.24% YoY to Rs 4262.50 crore in Q2 September 2025.

Powered by Capital Market - Live News

Biocon Ltd rose for a third straight session today. The stock is quoting at Rs 392.6, up 1.95% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.85% on the day, quoting at 25912.35. The Sensex is at 84598.03, up 0.87%. Biocon Ltd has added around 12.36% in last one month.

Meanwhile, Nifty Pharma index of which Biocon Ltd is a constituent, has added around 1.5% in last one month and is currently quoting at 22369.6, up 0.76% on the day. The volume in the stock stood at 63.02 lakh shares today, compared to the daily average of 25.08 lakh shares in last one month.

The benchmark November futures contract for the stock is quoting at Rs 393.3, up 1.77% on the day. Biocon Ltd is up 18.41% in last one year as compared to a 9.99% gain in NIFTY and a 3.35% gain in the Nifty Pharma index.

The PE of the stock is 0 based on TTM earnings ending June 25.

Powered by Capital Market - Live News